Home › Companies › XNCR

Xencor

Market cap $2.59B 75.0M shares (10-Q, Oct 30, 2026) × $34.50 close Nov 17, 2026

Most recent annual filing: 2026-02-25

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. XmAb541 readout2H 2026XmAb541 readout, 2H 2026, notable
  2. XmAb942 UC interim~YE 2026XmAb942 UC interim, ~YE 2026, material
  3. XmAb819 Ph3 readout1H 2027XmAb819 Ph3 readout, 1H 2027, notable
  4. XmAb412 Ph1 interim1H 2027XmAb412 Ph1 interim, 1H 2027, notable
  5. XmAb657 corporate update2027XmAb657 corporate update, 2027, routine
  6. XmAb942 UC topline~2H 2027XmAb942 UC topline, ~2H 2027, thesis-defining
  7. XmAb819 pivotal startYE 2027XmAb819 pivotal start, YE 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (28 active programs)

Technology platforms

XmAb Bispecific Fc Domain

Modular Fc engineering platform enabling multispecific antibody formats including 2+1 bispecific, CD3 T-cell engagers, CD28 co-stimulatory bispecifics, and trispecific formats. Applicable across oncology and autoimmune diseases.

Xtend Fc Domain

Engineered Fc domain designed to extend antibody half-life through FcRn receptor engagement on endothelial cells. Used in XmAb942, Ultomiris, tobevibart, and zaltenibart programs across IBD, PNH, and infectious disease.

Targets: FcRn

XmAb 2+1

XmAb 2+1 T-cell engager format designed to bind tumor antigens with high avidity/low affinity, enabling selective killing of high-antigen-density tumor cells while sparing low-density normal tissue; applied in solid tumor oncology programs

XenLock

Novel bispecific antibody platform enabling dual targeting of inflammatory pathways; used to develop XmAb412 (TL1A x IL-23p19) for autoimmune and inflammatory diseases; supports high-concentration, low-viscosity subcutaneous formulations

Targets: TL1A, IL-23p19

XmAb

XmAb protein engineering technology enabling modifications to antibody structure for new mechanisms of therapeutic action, including bispecific 2+1 formats, Xtend half-life extension, Immune Inhibitor Fc domains, and XenLock bispecific formats; applied across oncology and autoimmune disease programs.

Discontinued (1)

Capital (as filed)

Cash
$59.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
$2.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$486M cash, runway through 2028 per the update of Aug 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Xencor, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Xencor, Inc. (XNCR) — Scientific Deep Dive for XmAb819, XmAb942 and the XmAb Pipeline Solid balance sheet and diversified optionality but no de-risked near-term value driver, crown-jewel royalty in active dispute, and all wholly-owned programs entering crowded competitive fields.
  2. Speculative buy speculative UPDATE: Xencor (XNCR) - The Alexion Standoff Ends at $105 Million Alexion settled the disputed Ultomiris royalty at roughly full value ($105M cash), removing the single cleanest bear argument and restoring runway through 2028, while a dated ESMO podium slot for XmAb819 provides the next re-rating catalyst.
  3. Speculative buy speculative UPDATE: Xencor (XNCR) - The Hearing Problem Nobody Was Modeling Balance sheet continues to strengthen without dilution and XmAb541 earned its first regulatory designation, but on-target hearing toxicity caps monotherapy exposure and the 14% ovarian ORR is less exciting than earlier framing; everything funnels into the ESMO XmAb819 oral in October.
  4. Buy core UPDATE: Xencor (XNCR) - Madrid Delivers: The Dose-Response Is Real XmAb819's confirmed response rate rose with dose to 35–45% in heavily pretreated ccRCC including belzutifan-pretreated patients, more than double approved benchmarks, with a concrete regulatory path to a tivozanib-controlled RCT and runway extended into 2029 without dilution.
  5. Buy core UPDATE: Xencor (XNCR) - The Autoimmune Option Gets Its First Patients Plamotamab showed dose-dependent >50% CDAI reduction and deep memory B-cell depletion in RA with a clean safety profile, adding early clinical support for the autoimmune platform leg while XmAb819's registration path and extended runway remain the primary thesis drivers.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (22)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 29, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)